How to Cite
Abstract
The article presents the features of the clinical manifestation of multiple primary sporadic and heritable malignant tumors in 104 children who observed at Pediatric Oncology and Hematology Research Institute of «NN Blokhin's National Medical Research Center of Oncology» from 1998 to 2012. The age of patients at the time of occurrence of the second malignant tumor ranged from 2.8 to 28 years and averaged 15.6 years. The second neoplasia occurred significantly more frequently in the group of primary hemoblastosis, compared with the group of solid tumors - 8.7% versus 3.4%, respectively (p <0.0001). In children with multiple primaries, were found tumors that occur in common the most frequency. Retinoblastoma patients have an increased risk of developing sarcoma. Patients with Hodgkin's lymphoma have an increased risk of developing leukemia. In surviving children after treatment of the first neoplasia the thyroid, bone tissue and breast have a specific risk for the development of metachronous cancer and are target organs for control. Children with new hematopoietic tumors may be candidates for metachronous development of leukemia and bone tissue tumors. The using methods Next Generation Sequencing (NGS) and Multiplex Ligation-dependent Probe Amplification (MLPA) revealed germinal mutations in 12 children with of multiple primary tumors. The mutations in the TP53, RB1, CHEK2, FANCN/PALB2, MLH1, PMS2 genes identified in patients were associated with hereditary syndromes and an increased risk of developing second tumors, among which: sarcomas, brain tumors, hematopoietic tumors were the most frequent. It was shown that the second tumors can appear at the any age. Children who survived the treatment of the first tumor in later life should be monitored annually. Clinical management of children with multiple primary tumors requires a multidisciplinary approach.
References
Петров Н.Н. Руководство по общей онкологии. - Л.: Медгиз, 1961. - С. 48-51.
Шунько Е.Л. Сравнительный анализ особенностей развития вторых опухолей после химиотерапии, лучевой терапии и химиолучевой терапии первой опухоли // Фундаментальные исследования. - 2015. - № 1 (часть 8). - С. 1539-1543.
Ханов А.М. Эпидемиология, факторы риска и оптимизация диагностики при выявлении первично-множественных злокачественных опухолей: //Дисс.. канд. мед. наук. Москва, 1994.
Billroth Т. Die Allgemeine Chirurgische Pathologie and Therapie. 51 Vorlesungen // Ein Handbuch fur Studierende and Artze. Berlin: G Reimer. - 1889. - P. 934-953.
Петров Н.Н. Первичная одиночность и множественность злокачественных опухолей // Злокачественные опухоли. - 1947. - Т. 1. - С. 260-263.
Гореликова О.Н. Первично-множественные злокачественные опухоли // Вестник РОНЦ им. Н.Н. Блохина РАМН. - 1992. - Т 3. - № 4. - С. 53-61.
Jazbee J., Fraumeni J.F., Curtis R.E. et al. Chapter 1: Introduction. In: Curtis R.E. Freedman D.M., Ron E., Ries L. et al. New Malignancies among Cancer Survivors: SEER Cancer Registries, 1973-2000 // National Cancer Institute; Bethesda, MD. - 2006. - NIH Publ. - No. 05-5302.
Мерабишвили В.М. Регистрация и учет больных с первично-множественными злокачественными новообразованиями // Вопросы онкологии. - 2000. - Т. 46. - № 1. - С. 40-43.
Howlader N., Noone A.M., Krapcho M. et al. SEER Cancer Statistics Review, 1975-2011 // National Cancer Institute. - Bethesda, MD, 2015. - http://seer.cancer. gov/csr
Соркин В.М. К вопросу о регистрации учете больных с первично-множественными новообразованиями // Онкология. - 2001. - № 3. - С. 136-138.
Старинский В.В., Петрова Г.В., Харченко Н.В., Грецова О.П. основные показатели онкологической помощи населению России в 2000 г. // Новые информационные технологии в онкологической статистике / под ред. В.М. Мерабишвили, 2001. - С. 8-9.
Haffty B.G., Choi D.H., Goyal S. et al. Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups // Ann Oncol. -2009. - Vol. 20. - P. 16531659.
Noh J.M., Choi D.H., Baek H., Nam S.J. et al. Associations between BRCA Mutations in High-Risk Breast Cancer Patients and Familial Cancers other than Breast or ovary // J. Breast Cancer. -2012. - Vol. 15. - № 3. - Р. 283-287.
Sampson J.N., Wheeler W.A., Yeager M., Panagiotou O. et al. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types // J. Natl. Cancer Inst. - 2015. - Vol. 107. - № 12. - Р. 279-281.
Fritsche L.G., Gruber S.B., Wu Z., Schmidt E.M. et al. Association of Polygenic Risk Scores for Multiple Cancers in a Phenome-wide Study: Results from The Michigan Genomics Initiative // Am J. Hum Genet. - 2018. - Vol. 102. - № 6. - P. 1048-1061.
Luberti D., Schwartz D., Almog N. et al. Epithelial cells of different organs exhibit distinct patterns of p53-dependent and p53-independent apoptosis following DNA insult // Exp. Cell Res. - 1999. - Vol. 10. - № 252. - P. 123-133.
Li X., Kang J., Pan Q. et al. Genetic analysis in a patient with nine primary malignant neoplasms: a rare case of Li-Fraumeni syndrome // Oncol Rep. - 2016. - Vol.18. - № 1. - Р. 13-19.
Казубская Т.П., Козлова В.М., Ушакова Т.Л. и др. Изучение пенетрантности и фенотипа ретинобластомы // Вопросы онкологии. - 2018. - № 2. - С. 234-241.
Tomar S., Sethi R., Sundar G. et al. Mutation spectrum of RB1 mutations in retinoblastoma cases from singapore with implications for genetic management and counselling // PLos one. - 2017. - Vol. 12. - № 6. - P 1-2.
Nevanlinna H., Bartek J. The CHEK2 gene and inherited breast cancer susceptibility // Oncogene. - 2006. - Vol. 25. - P. 5912-5919.
Cybulski C., Gorski B., Huzarski T., Masojc B. et al. CHEK2 is a multiorgan cancer susceptibility gene // Am. J. Hum Genet. - 2004. - Vol. 75. - P 1131-1135.
De Rosa M., Fasano C., Panariello L. et al. Evidence for a recessive inheritance of Turcot's syndrome caused by compound heterozygous mutations within the PMs2 gene // Oncogene. - 2000. - Vol. 19. - № 13. - P 1719-1723.
Goodenberger M.L., Thomas B.C., Riegert-Johnson D., Boland C.R. et al. PMS2 monoallelic mutation carriers: the known unknown // Genet Med. - 2016. - Vol. 18. - № 1. - P 13-19.
Walsh T., Casadei S., Lee M.K., Pennil C.C. et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing // Proc. Natl. Acad. Sci. U S A. -2011. - Vol. 108. - P 8032-18037.
Chadwick R.B., Meek J.E., Prior T.W., Peltomaki P, de La Chapelle A. Polymorphisms in a pseudogene highly homologous to PMS2 // Hum. Mutat. - 2000. - Vol. 16. - № 6. - P. 530.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2019